The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg.
2-AG, 2-arachidonoylglycerol
AEA, anandamide
CAE, childhood absence epilepsy
CB1R, cannabinoid type-1 receptor
Childhood absence epilepsy
ECS, endocannabinoid system
EEG, electroencephalography
Electroencephalogram
Endocannabinoid system
GAERS
GAERS, Genetic Absence Epilepsy Rats from Strasbourg
LFP, local field potential
PAM, positive allosteric modulator
Positive allosteric modulator
SWD, spike and wave discharge
THC, Δ9-tetrahydrocannabinol
Type 1 cannabinoid receptor
ago-PAM, allosteric agonist and positive allosteric modulator
Journal
IBRO neuroscience reports
ISSN: 2667-2421
Titre abrégé: IBRO Neurosci Rep
Pays: Netherlands
ID NLM: 101775148
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
04
09
2021
revised:
19
01
2022
accepted:
21
01
2022
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Childhood absence epilepsy (CAE) is a non-convulsive seizure disorder primarily in children characterized by absence seizures. Absence seizures consist of 2.5-5 Hz spike-and-wave discharges (SWDs) detectable using electroencephalography (EEG). Current drug treatments are only partially effective and adverse side effects have spurred research into alternative treatment approaches. Recent research shows that positive allosteric modulation of the type-1 cannabinoid receptor (CB1R) reduces the frequency and duration of SWDs in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a model that recapitulates the SWDs in CAE. Here, we tested additional CB1R ago-PAMs, GAT591 and GAT593, for their potential in alleviating SWD activity in GAERS.
Identifiants
pubmed: 35128516
doi: 10.1016/j.ibneur.2022.01.006
pii: S2667-2421(22)00006-9
pmc: PMC8804275
doi:
Types de publication
Journal Article
Langues
eng
Pagination
121-130Informations de copyright
© 2022 Published by Elsevier Ltd on behalf of International Brain Research Organization.
Déclaration de conflit d'intérêts
None.
Références
Annu Rev Psychol. 2013;64:21-47
pubmed: 22804774
EMBO J. 2001 Dec 17;20(24):7033-40
pubmed: 11742980
J Neurol Neurosurg Psychiatry. 2010 Nov;81(11):1218-22
pubmed: 20802210
Epilepsia. 2013 Apr;54(4):635-43
pubmed: 23464801
Epilepsy Behav. 2017 May;70(Pt B):319-327
pubmed: 28190698
Biol Psychiatry. 2018 Nov 15;84(10):722-733
pubmed: 28823711
ACS Chem Neurosci. 2017 Jun 21;8(6):1188-1203
pubmed: 28103441
J Neurosci. 2009 Jan 14;29(2):371-80
pubmed: 19144837
Eur J Neurosci. 2018 Oct;48(8):2890-2902
pubmed: 29247465
Front Neurol. 2019 Jul 03;10:716
pubmed: 31333569
Drug Metab Rev. 2018 Feb;50(1):3-13
pubmed: 29355030
J Neurosci Methods. 2016 Feb 15;260:159-74
pubmed: 26068173
Neurobiol Dis. 2016 Oct;94:106-15
pubmed: 27282256
Cereb Cortex. 2015 Sep;25(9):2440-55
pubmed: 24646614
Drug Metab Rev. 2018 Feb;50(1):14-25
pubmed: 29355038
Eur J Neurosci. 2020 Dec 28;:
pubmed: 33370468
EMBO J. 2005 Sep 7;24(17):3026-37
pubmed: 16107881
J Neurosci Methods. 2013 Jan 30;212(2):195-202
pubmed: 23137652
Nat Rev Drug Discov. 2004 Sep;3(9):771-84
pubmed: 15340387
Eur J Neurosci. 2019 Sep;50(6):3046-3059
pubmed: 30889299
Epilepsy Behav. 2020 Jan;102:106722
pubmed: 31855784
J Neurosci. 2007 Jun 13;27(24):6590-9
pubmed: 17567820
Neuroscientist. 2003 Oct;9(5):398-403
pubmed: 14580123
Epilepsia. 2014 Dec;55(12):1959-68
pubmed: 25377760
Mol Pharmacol. 2019 Nov;96(5):619-628
pubmed: 31515283
Physiol Rev. 2016 Oct;96(4):1593-659
pubmed: 27630175
PLoS Biol. 2008 Dec 23;6(12):2683-97
pubmed: 19108604
Sci Transl Med. 2012 Feb 15;4(121):121ra19
pubmed: 22344687
Neuropharmacology. 2013 Jun;69:115-26
pubmed: 23206503
Neuropharmacology. 2021 Aug 1;193:108611
pubmed: 34000272
J Neurophysiol. 2005 Apr;93(4):2194-232
pubmed: 15525801
Exp Neurol. 2017 Oct;296:16-22
pubmed: 28658605
J Med Chem. 2021 Jun 24;64(12):8104-8126
pubmed: 33826336
Front Mol Neurosci. 2020 Apr 28;13:54
pubmed: 32410959
Epilepsy Behav. 2018 Mar;80:346-353
pubmed: 29402631
Pharmacol Res. 2018 Mar;129:475-481
pubmed: 29158048
Neuropharmacology. 2021 Jun 1;190:108553
pubmed: 33845076
Biochim Biophys Acta. 2013 Jul;1828(7):1572-8
pubmed: 22885138
J Med Chem. 2020 Jan 23;63(2):542-568
pubmed: 31756109
Sci Rep. 2021 May 19;11(1):10611
pubmed: 34012003
Sci Rep. 2018 Dec 18;8(1):17935
pubmed: 30560885
Epilepsia. 2010 Aug;51(8):1511-21
pubmed: 20132294
Neuropharmacology. 2019 Jun;151:1-12
pubmed: 30940536
Neuron. 2003 May 8;38(3):461-72
pubmed: 12741992
Brain. 2020 Aug 1;143(8):2341-2368
pubmed: 32437558
J Neurochem. 2013 Mar;124(5):584-9
pubmed: 23205875
Neuroscience. 2020 Mar 15;430:105-112
pubmed: 32017953
J Epilepsy Res. 2017 Dec 31;7(2):61-76
pubmed: 29344464
Eur J Neurosci. 2016 Jan;43(1):25-40
pubmed: 26490879